The study demonstrates that chlorophyll, the pigment responsible for photosynthesis, can act as a universal physical crosslinker that dramatically transforms the mechanical behavior of hydrogels. Crosslinking is the process by which polymer chains are tied together into a network, and it is the single most important determinant of a gel’s stiffness, toughness, and resilience. Traditional chemical crosslinkers form permanent covalent bonds, which can be toxic, difficult to control, and irreversible. Physical crosslinkers, by contrast, rely on reversible interactions, but finding one that is biocompatible, inexpensive, and sustainably sourced has remained a persistent challenge. Chlorophyll, a plant-derived small molecule that is abundant and renewable, turns out to satisfy all of these criteria at once.

The mechanism underlying this transformation is rooted in the amphiphilic chemistry of the chlorophyll molecule. In an aqueous pre-polymer solution, chlorophyll molecules spontaneously self-assemble through hydrophobic interactions, clustering into nanoscale aggregates. These nano-aggregations become dispersed throughout the hydrogel matrix and function as anchoring points, physically tethering neighboring polymer chains without forming any covalent bonds. The result is a network that can dissipate energy through the reversible breaking and reforming of these physical junctions, rather than failing catastrophically when stressed. This energy-dissipating architecture is precisely what allows the material to survive extreme compression and spring back to its original shape, a property that conventional hydrogels conspicuously lack.

The quantitative gains reported by the team are striking. In gelatin methacrylate hydrogels, a widely used biomaterial platform abbreviated here as GC, the maximum compressive strain rose from approximately 43 percent to at least 90 percent after chlorophyll incorporation. In practical terms, this means a patch that previously would have cracked or shattered under moderate squeezing can now be deformed by more than nine-tenths of its height and still maintain its structural integrity. The researchers showed that a chlorophyll-reinforced gel could be injected through a delivery device while compressed to 90.4 percent deformation, emerging on the other side as a coherent, functional patch. For minimally invasive medicine, where materials must often travel through catheters no wider than a drinking straw, this level of compressibility represents a genuine breakthrough.

Chlorophyll was not the only innovation at work. The team paired the pigment-based crosslinking with a solvent exchange process, in which the water inside the gel is progressively replaced by another solvent, promoting the formation of a macroporous structure. These large, interconnected pores act like microscopic shock absorbers: when the gel is compressed, the pore walls buckle and fold rather than fracturing, and when the load is released, the elastic network drives the pores to reopen. The combination of nanoscale physical crosslinking and macroscale porosity produces a material that is simultaneously soft, compressible, and resilient, a trio of properties that usually involves difficult trade-offs in hydrogel design. By addressing the problem at two different length scales simultaneously, the researchers achieved mechanical performance that neither strategy could deliver alone.

To showcase the clinical potential of the approach, the team turned to one of the most demanding applications in regenerative medicine: repairing heart tissue after a myocardial infarction. When heart muscle dies following a blocked coronary artery, the surviving tissue is left weakened and progressively remodels toward scar formation, ultimately leading to heart failure. Injectable cardiac patches offer a way to reinforce the damaged wall and deliver therapeutic function without open-heart surgery, but they must withstand enormous cyclic strains, roughly 40 million heartbeats per year, and must survive the trauma of injection. The researchers fabricated a conductive cardiac patch by depositing polypyrrole, an electrically conducting polymer, onto the chlorophyll-reinforced gelatin methacrylate matrix, producing a material designated GCP that could both conduct electrical signals and endure extreme deformation.

The scale of the demonstration is notable. Rather than testing small laboratory specimens, the team engineered a single patch measuring 36 millimeters in diameter, large enough to cover a substantial infarct region, and delivered it to the hearts of minipigs, an animal model whose cardiac anatomy and physiology closely resemble those of humans. The patch survived injection under high deformation and integrated into the beating heart, where its conductivity could support electrical coupling across the damaged region. In large-animal models of myocardial infarction, this kind of size fidelity matters enormously, because results obtained with tiny rodent-sized patches often fail to translate to the scale required for human therapy.

The functional outcomes added a second layer of significance. Beyond its mechanical and conductive roles, chlorophyll proved to be an intrinsic antioxidant reservoir within the patch. Infarcted heart tissue is bathed in reactive oxygen species generated by inflammation and mitochondrial dysfunction, and this oxidative stress drives further cell death and adverse remodeling. By releasing antioxidant activity directly at the injury site, the chlorophyll-containing patch counteracted this hostile chemical environment. In the porcine model, animals receiving the treatment showed an 11 percent improvement in ejection fraction, the standard clinical measure of how much blood the left ventricle pumps with each contraction. An improvement of that magnitude, achieved by a biomaterial intervention rather than a drug or a device, would be clinically meaningful if it carried through to human trials.

The broader implications of the work extend well beyond cardiology. Because chlorophyll functions as a universal physical crosslinker, the strategy should in principle apply to many hydrogel chemistries beyond gelatin methacrylate, opening a route to compressible, injectable versions of materials used in cartilage repair, wound healing, drug delivery, and soft robotics. The sustainability angle is equally compelling: chlorophyll is arguably the most abundant pigment on the planet, extracted annually in industrial quantities as a byproduct of the food and agricultural industries, and its use as a biomaterial additive requires no exotic synthesis. A crosslinking strategy that is simultaneously plant-derived, inexpensive, biocompatible, and mechanically transformative is a rare combination, and it illustrates how revisiting familiar natural molecules with fresh engineering eyes can unlock solutions that decades of synthetic chemistry have struggled to match. If the pig-heart results can be reproduced in clinical settings, the humble green molecule that powers photosynthesis may one day help power the recovery of failing human hearts.

Subject of Research: Chlorophyll-based physical crosslinking for compressible injectable hydrogel cardiac patches

Article Title: Chlorophyll as a sustainable crosslinking strategy for engineering highly compressible hydrogels

Article References: Xu, K., Zhao, C., Liu, Y., Liu, J., Xing, X., Ojo, O. W., Wu, M., Wang, Q., Xing, M. M. Q., & Wang, L. (2026). Chlorophyll as a sustainable crosslinking strategy for engineering highly compressible hydrogels. Nature Communications. https://doi.org/10.1038/s41467-026-77673-z

Image Credits: AI Generated

DOI: 10.1038/s41467-026-77673-z

Keywords: chlorophyll, hydrogels, crosslinking, cardiac patch, myocardial infarction, injectable biomaterials, gelatin methacrylate, polypyrrole, antioxidant, tissue engineering, minipig model, biomedical materials

The research, published in PLOS Genetics by Jake Colautti, Alexander C. Anderson, Wyatt P. K. Clark, and Lindsey S. Marmont, focuses on a long-standing puzzle in bacterial cell biology: how dividing cells switch on the synthesis of septal peptidoglycan, the new cell wall material that must be forged at exactly the right place and time as a bacterium splits in two. In rod-shaped bacteria such as P. aeruginosa and the better-studied Escherichia coli, this task falls to a pair of enzymes known as FtsW and FtsI. FtsW is a member of the SEDS family of membrane proteins, while FtsI is a class B penicillin-binding protein, and together the FtsWI complex carries out the essential work of polymerizing and cross-linking the peptidoglycan strands at the division septum. Without properly regulated FtsWI activity, the cell cannot complete division and dies.

For years, microbiologists have believed that FtsWI sits in a dormant state until it receives an activating signal from the rest of the divisome, the elaborate protein assembly that assembles at the future site of division. The accepted model describes an allosteric cascade: the late-arriving divisome protein FtsN, considered the final trigger of cytokinesis, transmits its signal through the FtsQ, FtsL, and FtsB proteins, which form a complex known as FtsQLB, and this complex in turn stimulates FtsWI to begin building the septum. Yet the molecular details of this handoff have remained murky, and the picture appears to differ from one bacterial species to another. The new study set out to clarify how this regulatory cascade works in P. aeruginosa, an organism that is both a formidable pathogen and, until recently, less genetically tractable than E. coli.

The team’s strategy exploited a key genetic feature: the gene encoding FtsN, while essential, can be studied through conditional essentiality, meaning the researchers could remove it and then search for mutations elsewhere in the genome that allow cells to survive without it. This approach, often called a suppressor screen, is a powerful way to identify the components of a regulatory pathway. If a mutation in another gene can compensate for the loss of FtsN, that gene very likely participates in the same process. When the researchers deleted ftsN and looked for survivors, they found them, and the compensating mutations mapped to a specific region of the ftsI gene encoding the non-enzymatic pedestal domain of the FtsI protein.

The pedestal domain is a region of FtsI that sits outside the enzyme’s catalytic machinery, and it had not previously been considered a major control point for septal cell wall synthesis. The substitutions the team identified did more than merely rescue the loss of FtsN. The mutant cells also suppressed the toxic effects of activation-defective ftsL alleles, versions of FtsL that dominantly disrupt division when present, and they shortened cell length even in an otherwise normal genetic background. Together, these observations indicate that the pedestal mutations change how FtsWI is regulated, allowing the enzyme complex to escape its dependence on stimulation by both FtsN and the FtsQLB complex. In effect, the mutations rewire the switch that normally holds septal peptidoglycan synthesis in check until the divisome is fully assembled.

To understand where these substitutions sit in three-dimensional space, the researchers mapped them onto the recently determined structure of the P. aeruginosa FtsQLBWI complex. The result was striking: rather than clustering at a single site, the mutations grouped onto distinct surfaces of the pedestal domain. Some variants localized to the interface where FtsI contacts FtsL, consistent with the idea that the FtsQLB complex physically transmits its activating signal to FtsWI through this contact. Others sat on the opposite face of the pedestal, suggesting that this surface engages a different regulatory input, possibly FtsN itself or another partner in the divisome. The pedestal domain, in other words, behaves as an integration point where multiple signals converge to control the timing and magnitude of septal cell wall construction.

The most consequential twist came from a clinical observation. Several of the pedestal substitutions identified in the study had previously been found in clinical isolates of P. aeruginosa showing increased resistance to aztreonam, a monocyclic β-lactam antibiotic that is one of the few options remaining against multidrug-resistant Gram-negative infections. That overlap prompted the team to ask a direct question: do these cell-division regulatory mutations change how susceptible the bacterium is to β-lactam antibiotics, which kill cells by sabotaging cell wall synthesis?

The answer depended on which surface of the pedestal domain was altered. Variants affecting the FtsI-FtsL interface modestly reduced the bacterium’s susceptibility to multiple β-lactam antibiotics, nudging the minimum inhibitory concentrations upward. Far more dramatic was the effect of a variant on the opposite face of the pedestal: this mutation produced striking hypersusceptibility to the same drugs, but only when FtsN was present. In other words, a single amino acid change in a non-enzymatic region of a cell wall synthase could either harden the pathogen against β-lactams or render it exquisitely vulnerable, depending on its position and on the presence of the divisome’s triggering protein.

These results carry two significant implications. First, they establish the FtsI pedestal domain as a central regulatory hub for FtsWI, resolving long-standing uncertainty about how the FtsN-to-FtsQLB-to-FtsWI cascade is wired in P. aeruginosa and demonstrating that the non-enzymatic architecture of a cell wall synthase can govern its activity. Second, and more urgently, they reveal a previously unrecognized relationship between divisome regulation and β-lactam susceptibility. Antibiotic resistance in P. aeruginosa is usually attributed to enzymatic drug destruction, efflux pumps, and reduced permeability, but this work shows that subtle alterations in the regulation of septal peptidoglycan synthesis can also shift the balance between life and death in the presence of β-lactams, and that such alterations already exist in clinical isolates.

The study also suggests new directions for drug discovery and surveillance. If the pedestal domain integrates the signals that unleash septal cell wall synthesis, then molecules that lock the domain into a hypersusceptible state, mimicking the effect of the sensitizing mutation, could potentially restore the potency of β-lactams against resistant strains. Conversely, sequencing efforts that monitor pedestal-domain residues in clinical P. aeruginosa populations might provide early warning of emerging β-lactam tolerance that conventional resistance mechanisms would miss. As the authors note, the work highlights the potential relevance of divisome regulation to β-lactam resistance in the clinic, transforming a fundamental question about bacterial cell biology into a matter of direct medical consequence.

Subject of Research: Regulation of septal peptidoglycan synthesis and its effect on β-lactam antibiotic susceptibility in Pseudomonas aeruginosa

Article Title: Altered regulation of septal peptidoglycan synthesis modulates β-lactam susceptibility in Pseudomonas aeruginosa

Article References: Colautti, J., Anderson, A. C., Clark, W. P. K., & Marmont, L. S. (2026). Altered regulation of septal peptidoglycan synthesis modulates β-lactam susceptibility in Pseudomonas aeruginosa. PLOS Genetics, 22(9), e1012319. https://doi.org/10.1371/journal.pgen.1012319

Image Credits: AI Generated

DOI: 10.1371/journal.pgen.1012319

Keywords: Pseudomonas aeruginosa, cell division, peptidoglycan synthesis, FtsI, FtsN, FtsQLB complex, divisome, beta-lactam antibiotics, aztreonam, antibiotic resistance, SEDS-bPBP synthase, pedestal domain

The protein at the center of the study is GTBP-1, the worm equivalent of human G3BP1, a molecule long recognized as a master organizer of stress granules. Stress granules are dynamic, membrane-less assemblies of stalled messenger RNAs and proteins that form rapidly when cells encounter harsh conditions such as heat, oxidative damage, or nutrient deprivation. By temporarily sequestering mRNAs, these condensates pause protein production and shield RNA transcripts from degradation, buying the cell time to recover. In mammalian cells, G3BP1 acts as a molecular switch that triggers the phase separation driving stress granule assembly, making its worm counterpart an obvious candidate for investigating how germ cells weather thermal stress.

To probe GTBP-1’s role, the team used CRISPR/Cas9 to generate knockout worms lacking the gene entirely. The results were strikingly temperature-dependent. At cool temperatures of 15 and 20 degrees Celsius, gtbp-1 mutants actually produced more offspring than normal worms, suggesting the protein normally restrains reproduction under benign conditions. But when animals were raised at 25 degrees Celsius, the mutants became severely infertile. Microscopy showed that the germline tissue itself remained largely intact in the heat-stressed mutants, yet embryos were rarely seen, indicating that the fertility collapse stems from a failure in embryo production rather than a wholesale loss of reproductive tissue. GTBP-1, it appears, is dispensable or even slightly inhibitory when life is easy, but essential when the heat is on.

Fluorescent tagging revealed the protein’s dramatic behavioral shift. Under standard laboratory conditions, GFP-labeled GTBP-1 drifted diffusely through the cytoplasm of epidermal cells, germ cells, and early embryos. When worms were chronically cultured at 25 degrees Celsius, punctate GTBP-1 granules appeared in the germline of a subset of animals, though not in skin cells. Acute heat shock at 37 degrees Celsius for just 30 minutes produced even more pronounced granules across multiple tissues, with GTBP-1 condensing into structures at the perinuclear region surrounding germ cell nuclei, within the central rachis of the gonad, and in the cytoplasm of oocytes. The message was clear: heat stress rapidly reorganizes this protein from a dispersed state into concentrated assemblies precisely where reproductive RNA management happens.

The researchers then dissected which parts of the protein matter. GTBP-1 carries several conserved domains: an NTF2 domain, an intrinsically disordered region, an RNA recognition motif, and an arginine/glycine-rich region. Deleting the NTF2 domain nearly abolished GTBP-1’s recruitment into heat-induced granules, confirming that this module, already known to drive G3BP1-mediated condensation in mammals, is the engine of granule assembly. Deleting the disordered region or the RGG domain told a different story: granules still formed during heat stress but lingered far longer during recovery, indicating these domains govern the fluidity and reversibility of the condensates. Notably, all four domain-deletion variants showed reduced fertility at 25 degrees Celsius, and the severity of the reproductive defects did not simply track with granule defects, hinting that GTBP-1’s contributions to reproduction extend beyond granule formation, possibly through RNA-related functions of its binding domains.

Where exactly do these granules sit within the crowded landscape of germ cell structures? The C. elegans germline hosts an impressive array of perinuclear condensates, including P granules, Z granules, Mutator foci, SIMR foci, D granules, E granules, and P-bodies, each with distinct molecular markers and functions in small RNA metabolism and gene silencing. By crossing their GFP::GTBP-1 strain with strains carrying fluorescent markers for all seven compartments, the team quantified overlap after heat shock. The verdict was unambiguous: GTBP-1 showed its strongest correlation with the P-body marker CGH-1, with moderate associations to several other compartments and a notably weaker link to Z granules. The same GTBP-1 and CGH-1 pairing appeared in both mitotic and meiotic regions of the germline and persisted in early embryos through the two-cell, four-cell, and multicellular stages.

P-bodies are condensates dedicated to mRNA storage and decay, and their intimate relationship with stress granules has been documented in yeast and mammalian cells, where the two structures exchange messenger ribonucleoprotein components under stress. The worm study adds a germline dimension to this picture. When the researchers depleted core P-body components such as CGH-1, EDC-3, or IFET-1 by RNA interference, heat-induced GTBP-1 enrichment dropped significantly, both in the perinuclear region and in the rachis, while total GTBP-1 protein levels remained unchanged. In contrast, disrupting P, Z, Mutator, or E granule components did not prevent GTBP-1 from forming puncta. P-body organization, in other words, is specifically required for efficient GTBP-1 granule assembly during heat stress, positioning these mRNA-decay condensates as scaffolds or partners for the stress response in germ cells.

A candidate screen of 35 genes encoding stress granule proteins and predicted GTBP-1 interactors added further regulators to the network. Loss of PQN-59, a protein related to human UBAP2L, reduced both GTBP-1 granule enrichment and granule number, whereas depletion of the stress granule protein TIAR-1 had little effect. Two other hits stood out: LAF-1, a DEAD-box RNA helicase best known as a P granule component that drives phase separation, and SMO-1, the worm’s sole SUMO protein, implicating SUMOylation, a stress-elevated protein modification, in granule regulation. None of these depletions changed total GTBP-1 abundance, and none rescued the fertility of gtbp-1 mutants at 25 degrees Celsius, showing that granule disruption alone cannot restore reproduction.

The most surprising discovery came from a forward genetic screen of roughly 20,000 mutagenized genomes, hunting for mutations that restore fertility to heat-stressed gtbp-1 mutants. Only one suppressor emerged repeatedly: loss-of-function mutations in rsks-1, the worm homolog of ribosomal S6 kinase, a key effector of the mTOR signaling pathway that governs translation, growth, and aging. Knocking out rsks-1 by several independent means consistently rescued the brood size of gtbp-1 mutants at 25 degrees Celsius, while depleting a panel of well-known longevity genes did not, arguing that the effect is specific rather than a general slowdown of aging pathways. Heat-shock survival assays added nuance: rsks-1 mutants alone were more sensitive to lethal heat, but combining rsks-1 loss with gtbp-1 loss restored wild-type survival, suggesting the two proteins counterbalance each other in stress responses.

RSKS-1 also turned out to be a heat-responsive granule protein in its own right. Normally distributed throughout the cytoplasm and nucleus, it relocalized after heat shock into perinuclear granule-like structures in the germline and oocytes, and these structures overlapped substantially with CGH-1-positive P-bodies, yielding a mean Pearson’s correlation coefficient of about 0.67. Loss of RSKS-1 delayed the appearance of GTBP-1 granules and reduced their number during heat stress without changing how strongly GTBP-1 concentrated within individual granules, indicating that the kinase controls the kinetics and abundance of granule formation rather than granule composition. Together, the findings sketch a working model in which heat stress recruits GTBP-1, along with PQN-59, TIAR-1, and RSKS-1, into perinuclear P-body-associated condensates, linking mTOR-dependent translational control to the RNA granule remodeling that keeps fertility intact across a changing thermal world. As heat waves intensify and reproductive health under thermal stress becomes an ever more pressing question from agriculture to human fertility, this humble worm offers a molecular map of how germ cells fight back.

Subject of Research: Heat stress-induced GTBP-1 stress granule assembly and its association with P-bodies in the C. elegans germline

Article Title: Heat stress promotes GTBP-1 association with perinuclear P-bodies in the C. elegans germline

Article References: Heat stress promotes GTBP-1 association with perinuclear P-bodies in the C. elegans germline. (n.d.). https://doi.org/10.1371/journal.pgen.1012336

Image Credits: AI Generated

DOI: 10.1371/journal.pgen.1012336

Keywords: stress granules, GTBP-1, G3BP1, C. elegans, germline, heat stress, P-bodies, fertility, mTOR signaling, RSKS-1, phase separation, RNA granules

The material at the heart of the study comes from the sponge Haliclona sp., whose skeleton is built from spicules—slender, needle-shaped rods of biosilica. In earlier work, the same group showed that intact spicules, massaged briefly into the skin, create dense fields of nanometer-scale microchannels that boost penetration of small drugs. Those channels, however, proved too narrow for biomacromolecules, which typically range from a few to hundreds of kilodaltons. The researchers’ new idea was to etch the spicules themselves, dissolving away the tip and, unexpectedly, the entire axial core to leave a continuous hollow channel running the length of each needle. This transformation converts each spicule from a solid puncturing pin into something closer to a microscopic drinking straw embedded in the skin.

Manufacturing the hollow structures required careful optimization of an alkaline etching process. The team immersed purified spicules in sodium hydroxide solutions of varying concentration and duration, then evaluated how many spicules developed open tips, how large the resulting channels were, and whether the etched structures retained the mechanical strength needed to pierce skin. The harshest condition tested—2 molar sodium hydroxide for 72 hours—produced the widest openings and highest opening rates but visibly degraded structural integrity. The sweet spot turned out to be 2 molar NaOH for 48 hours, which maximized hollow-channel formation while preserving the spicules’ ability to withstand handling and skin insertion. Scanning electron microscopy of cross-sections taken at the tip, mid-shaft, and base revealed a continuous internal lumen, and confocal microscopy after Nile Red staining confirmed that the channels readily admit fluid and dissolved compounds.

The etching pattern itself has an elegant biological explanation. Siliceous sponge spicules are built around a proteinaceous axial filament, and the alkaline treatment appears to preferentially dissolve along this central core, carving out the hollow channel along a pre-existing biological template. This means the manufacturing process exploits the sponge’s own architecture rather than fighting it—a rare example of a natural biomaterial being upgraded through a one-step chemical modification into something functionally analogous to an engineered hollow microneedle array, but without any of the cleanroom microfabrication that synthetic microneedles demand.

With the hollow spicules in hand, the researchers benchmarked them against a formidable lineup of competitors in Franz diffusion cell experiments using fresh porcine skin: intact spicules, conventional microneedle patches, dermaroller devices, iontophoresis, and plain subcutaneous injection. For sodium fluorescein, a small hydrophilic tracer, hollow spicules alone achieved total skin absorption of roughly 24 percent, rising to nearly 43 percent when paired with a 15-minute course of low-current iontophoresis. The combination produced a synergistic index of 1.44, meaning the two techniques together outperformed the sum of their individual effects. For larger fluorescent dextrans of 20, 40, and 150 kilodaltons, the gap widened dramatically. With the 20-kilodalton dextran, hollow spicules plus iontophoresis pushed absorption to about 35 percent with a synergistic index of 3.29, while intact spicules combined with iontophoresis showed no synergy at all—clear evidence that the hollow channels, not merely the puncture sites, were doing the heavy lifting.

Dose dependence and distribution uniformity emerged as two further advantages. When the team varied the amount of hollow spicules applied, penetration of the 150-kilodalton dextran scaled accordingly, giving clinicians a tunable knob for dosing. More striking was the spatial pattern: biomacromolecules delivered through spicule-treated skin spread evenly across the entire treated area, with no significant concentration differences among randomly sampled sites. Subcutaneous injection, by contrast, produced a hot spot at the needle entry point with essentially no detectable drug 5 millimeters or 1 centimeter away. For depot drugs, that pooling is sometimes desirable, but for vaccines and immunotherapies meant to engage skin-resident immune cells, uniform distribution could translate into more consistent uptake and fewer local adverse effects.

The platform’s most clinically resonant demonstration involved an antibody fragment. The team compared hollow spicules against laboratory-fabricated dissolving microneedle patches—10-by-10 arrays of quadrangular pyramidal needles, each about 820 micrometers tall and mechanically robust enough to withstand roughly 0.8 newtons of compressive force—for delivering a shark-derived anti-PD-L1 variable new antigen receptor, a model antibody-like therapeutic. The hollow spicules achieved total skin absorption of about 25 percent, roughly doubling the microneedle patch result of 11.5 percent and more than quadrupling the untreated control. Because antibody drugs represent one of the fastest-growing classes of biologics yet remain almost entirely injection-bound, a topical route that outperforms microneedles would be a meaningful advance for patients who self-administer these therapies.

To test whether the effect matters biologically, not just chemically, the researchers delivered ovalbumin, a classic model antigen, to guinea pigs over consecutive days and tracked immune activation. Both the injection group and the hollow-spicule group showed visible immune reactions by day 2, and by day 8 the spicule group’s responses, while milder than injection, remained significantly stronger than controls and intact-spicule groups. Blood analysis told the same quantitative story: ovalbumin-specific IgE levels were markedly elevated in the spicule group, and interleukin-4 concentrations showed no significant difference from the injection group. In other words, a topical massage of sponge-derived microneedles provoked an immune response functionally comparable to a needle in the flesh—a result with obvious implications for needle-free vaccination.

Safety data were encouraging but appropriately caveated. Mild redness and swelling after application resolved within 48 to 72 hours, and histological counts of immune cells in treated skin spiked to roughly 550 cells per analyzed region at 24 and 48 hours before falling back to baseline levels by day 10, statistically indistinguishable from untreated controls. Repeated application produced no chronic inflammatory infiltration, and examination of major organs revealed no abnormalities. The authors are candid, however, about a longer-term concern: silica is a recognized granulomatogenic material, and cutaneous silica granulomas can appear months or even years after exposure. Their 10-day observation window cannot rule out such delayed reactions, and the team calls for extended follow-up studies, including polarized-light assessment for birefringent particles, before the platform moves toward human use.

The study also contributes a quantitative framework for predicting how drugs will behave under spicule treatment. Because hollow spicules remain embedded in skin during use, they generate annular channels rather than the funnel-shaped perforations left by removable microneedles. Building on established microporous-skin permeability models, the researchers derived and fitted an equation capturing the dependence of permeability on molecular weight and oil-water partitioning across six test compounds, with the expected inverse relationship to molecular weight dominating the tested range. The team notes that validation in ex vivo human skin and clinical studies will be essential, since animal skin differs from human skin in barrier structure and immune responsiveness. Still, the combination of natural abundance, batch-to-batch dimensional consistency, low manufacturing cost, tunable dosing, uniform drug spread, and demonstrated vaccine-grade immune activation makes hollow sponge spicules one of the more compelling entries yet in the race to retire the hypodermic needle.

Subject of Research: Transdermal delivery of biomacromolecules using hollowed marine sponge spicules as natural microneedles

Article Title: Enhanced skin delivery of biomacromolecules using hollow sponge spicules

Article References: Mou, D., Yang, M., Jia, M., Liu, Y., Chen, J., Xiao, X., & Chen, M. (2026). Enhanced skin delivery of biomacromolecules using hollow sponge spicules. Bioengineering & Translational Medicine, 11(5), Article e70149. https://doi.org/10.1002/btm2.70149

Image Credits: AI Generated

DOI: 10.1002/btm2.70149

Keywords: drug delivery, microneedles, sponge spicules, transdermal, biomacromolecules, vaccination, biologics, iontophoresis, biosilica, skin barrier, antibody delivery, marine biotechnology

Cardiovascular disease remains the leading cause of death worldwide, and much of that mortality traces back to vascular dysfunction, the failure of blood vessels to develop properly or to respond correctly to physiological stress. Understanding why vessels fail requires experimental models that capture the complexity of human vascular tissue, something that two-dimensional cell monolayers have never managed to do convincingly. Blood vessel organoids derived from human pluripotent stem cells address this gap by self-organizing into three-dimensional structures containing the key cellular constituents of vessel walls, providing researchers with a living miniature of human vasculature that can be studied in a dish.

The original differentiation framework that made such organoids possible was established by Wimmer and colleagues, whose protocol guided human pluripotent stem cells through a carefully choreographed sequence of developmental signals so that they matured into vascular tissue. That pioneering method, however, was built around bulk cultures in which large numbers of cell aggregates developed together in shared vessels. In such crowded conditions, neighboring cell spheres readily fuse with one another, and researchers must later perform laborious dissection to separate individual organoids. The fusion problem also means that aggregates cannot be tracked as independent experimental units, which limits the design of experiments that require many distinct conditions to be compared side by side.

The Bengbu team, led by Zhuxin Zhou, Benchi Feng, and senior authors Yong Gao and Shiyuan Chen, adapted the established differentiation framework to a U-bottom 96-well ultra-low-attachment plate. The key design choice is elegant in its simplicity: an equal number of human pluripotent stem cells is seeded into each individual well, and each well then gives rise to exactly one cell aggregate that differentiates into one blood vessel organoid. Because the U-shaped bottom of each well concentrates the cells at its center while the ultra-low-attachment surface prevents them from sticking to the plastic, the developing aggregate sits in its own private microenvironment. The one-aggregate-per-well configuration physically prevents fusion between neighboring aggregates, since each aggregate is confined to a separate well from the very start of differentiation.

This physical isolation has consequences that go far beyond convenience. Each blood vessel organoid can be cultured, treated, sampled, collected, and analyzed completely independently of its neighbors. A researcher can expose one well to a drug candidate, another to a different dose, and a third to a control vehicle, all while every organoid remains an intact, individually traceable unit. Different wells on the same plate can be assigned to distinct cell lines, treatment groups, doses, culture conditions, or time points, and the number of wells actually occupied can be adjusted freely to match the scale of any given experiment. A pilot study might use a single row of eight wells, while a full screening campaign could fill the entire plate with ninety-six independently manipulated organoids.

To demonstrate that the platform produces genuine vascular tissue, the researchers generated blood vessel organoids from two different sources of human pluripotent stem cells: the widely used H9 embryonic stem cell line and induced pluripotent stem cells, which are adult cells reprogrammed back into an embryonic-like state. They then assessed whether the resulting organoids expressed and correctly organized the molecular hallmarks of blood vessel tissue. Two complementary techniques anchored this quality control. Reverse transcription quantitative polymerase chain reaction, or RT-qPCR, measured the levels of messenger RNA for vascular marker genes, revealing which cell-type-specific genetic programs had been activated during differentiation. Immunofluorescence staining, in turn, visualized where the corresponding proteins accumulated within the organoids, confirming that vascular cells were not merely present but properly organized into vessel-like structures.

The practical advantages of the 96-well format extend to cost and labor, two factors that often determine whether an organoid method spreads through the research community. Conventional organoid protocols consume substantial quantities of expensive reagents and consumables, including type I collagen and Matrigel, the extracellular matrix mixtures used to support three-dimensional growth. Because each well in the new platform requires only the material needed for a single organoid, the total consumption of these costly components drops considerably, making the method more cost-effective for laboratories with limited budgets. The platform also eliminates much of the repetitive handling that burdens traditional workflows. The authors specifically highlight the reduction in rehanging operations, the manual transfers used to keep developing aggregates properly suspended, and the subsequent dissection work needed to separate fused organoids, saving both time and physical effort at the bench.

Flexibility is another defining feature of the system. Because plate occupancy is adjustable, the number of organoids generated can be tuned precisely to the requirements of each experiment rather than dictated by the protocol. A laboratory studying a rare patient-derived induced pluripotent stem cell line might need only a handful of organoids for a characterization study, while a pharmacology group testing a panel of vascular drugs might need hundreds across multiple plates. The platform accommodates both extremes on the same standardized hardware, which means results from different laboratories using the system should be more directly comparable than results from bespoke, hand-built organoid setups.

The researchers position the platform as a foundation for future compound-testing applications, and the logic is straightforward. Drug screening in cardiovascular research has long suffered from a shortage of human-relevant three-dimensional models that can be produced at sufficient scale and consistency. A 96-well plate is the native format of automated liquid handlers, plate readers, and high-content imaging systems, so organoids grown in this configuration slot directly into existing laboratory automation infrastructure. Multiplexed experiments, in which many compounds, doses, and genetic backgrounds are tested simultaneously, become a realistic prospect rather than an aspiration, and the ability to run distinct cell lines on a single plate opens the door to direct comparisons between healthy and disease-derived vascular tissue under identical conditions.

The work arrives at a moment when organoid technology is maturing from a specialist curiosity into a mainstream platform for disease modeling and drug development, and it addresses one of the field’s most persistent bottlenecks: throughput. By preserving the biological logic of the established differentiation framework while redesigning its physical container, the Bengbu team has created a bridge between the qualitative richness of blood vessel organoids and the quantitative demands of modern biomedical research. The study received support from the Research Fund for the Construction and Transformation of Vascular Organoid of The First Affiliated Hospital of Bengbu Medical University and from the Key Project of Natural Science Research in Universities of Anhui Province, and the article is published open access under a Creative Commons license. For laboratories worldwide that have hesitated to adopt vascular organoids because of cost, labor, or scalability concerns, the message of this platform is that the barrier to entry may now be no higher than a standard cell culture plate.

Subject of Research: A 96-well ultra-low-attachment platform for constructing human pluripotent stem cell-derived blood vessel organoids

Article Title: A 96-well platform for blood vessel organoid construction

Article References: Zhou, Z., Feng, B., Cheng, X., Zhang, X., Yu, C., Gao, Y., & Chen, S. (2026). A 96-well platform for blood vessel organoid construction. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06388-7

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06388-7

Keywords: blood vessel organoids, human pluripotent stem cells, 96-well plate, ultra-low-attachment, vascular differentiation, cardiovascular disease modeling, high-throughput screening, organoid platform, embryonic stem cells, induced pluripotent stem cells, multiplexed testing, three-dimensional culture

Erucic acid is a monounsaturated omega-9 fatty acid found abundantly in the seed oils of plants in the mustard and brassica families, including rapeseed and mustard. Although it has long been viewed with caution in the food industry because of concerns about cardiac effects at very high intakes, recent research has begun to reveal a more nuanced picture. Prior work by some of the same authors and by other groups has suggested that erucic acid possesses antioxidant and anti-inflammatory properties, and studies in mice have indicated that erucic acid-rich oils can improve insulin resistance. The new study set out to test whether these properties translate into tangible protection for kidneys under sustained diabetic stress.

To model the disease, the researchers induced diabetes in rats with a single intraperitoneal injection of streptozotocin, a compound that selectively destroys the insulin-producing beta cells of the pancreas. Streptozotocin-induced diabetes is a well-established experimental platform for studying diabetic nephropathy because the resulting chronic hyperglycemia triggers many of the same metabolic and structural changes seen in human patients, including albumin leakage into the urine, elevated blood urea nitrogen, and progressive damage to the glomeruli and tubules. Once diabetes was established, the animals received erucic acid orally at doses of 10 or 20 milligrams per kilogram of body weight once daily for eight weeks, allowing the team to assess both short- and longer-term effects on metabolic control and renal health.

The metabolic results were striking. Rats treated with erucic acid showed significantly reduced blood glucose and glycated hemoglobin, or HbA1c, the long-term marker of blood sugar control. At the same time, the treatment raised circulating insulin and adiponectin—a hormone with insulin-sensitizing and anti-inflammatory actions—while lowering resistin, an adipokine implicated in insulin resistance and inflammation. The fatty acid also corrected the dyslipidemia that typically accompanies uncontrolled diabetes, reducing total cholesterol and triglycerides while raising protective high-density lipoprotein cholesterol. Because lipid abnormalities and poor glycemic control both feed the vicious cycle of kidney damage in diabetes, these systemic improvements likely contributed to the renal benefits observed downstream.

The most consequential findings concerned kidney function itself. Diabetic rats in the untreated group displayed the classic biochemical signature of nephropathy: elevated serum creatinine, elevated blood urea nitrogen, increased urinary albumin excretion, and increased 24-hour urine volume, all reflecting a failing filtration barrier. Erucic acid treatment reversed these trends in a dose-dependent manner, lowering creatinine and urea levels, reducing albumin loss, decreasing excessive urine output, and improving creatinine clearance—a direct measure of how effectively the kidneys filter waste from the blood. Histopathological examination of kidney tissue corroborated the biochemical data, showing preservation of renal architecture in treated animals compared with the structural deterioration evident in untreated diabetic controls.

Delving into mechanism, the researchers focused on oxidative stress, a central engine of diabetic kidney injury. Chronically high glucose floods the kidney with reactive oxygen species that overwhelm its antioxidant systems, damaging lipids, proteins, and DNA. In the diabetic rats, the activities of the key antioxidant enzymes superoxide dismutase and catalase, along with levels of the cellular antioxidant glutathione, were depleted. Erucic acid supplementation restored these defenses to near-normal levels. Consistently, markers of oxidative damage fell: malondialdehyde, a product of lipid peroxidation, and nitric oxide, which at pathological levels contributes to inflammatory tissue injury, were both significantly reduced in the kidneys of treated animals.

Inflammation provided the second mechanistic thread. Diabetic nephropathy is increasingly understood as an inflammatory disease in which immune cells and pro-inflammatory signaling molecules accelerate the scarring and functional decline of renal tissue. The study found that erucic acid downregulated the expression of the major pro-inflammatory cytokines tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 in kidney tissue. This anti-inflammatory shift parallels findings from the group’s earlier work, which showed that erucic acid could suppress inflammatory cytokine expression and NF-kappa B signaling in models of memory impairment and cancer, suggesting that the fatty acid acts on conserved inflammatory pathways that operate across multiple organ systems.

Particularly noteworthy was the effect on early injury biomarkers. Kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin, known as KIM-1 and NGAL, are proteins whose expression rises sharply when tubular cells are under stress, often before conventional markers like creatinine begin to move. They are increasingly used in clinical research as sensitive harbingers of kidney damage. In the present study, erucic acid significantly decreased renal KIM-1 and NGAL levels, indicating that the compound not only preserves gross filtration function but also protects the tubular cells at the cellular level, potentially intercepting injury at an earlier stage of the disease process.

Complementing the laboratory experiments, the team performed in silico molecular docking studies to explore how erucic acid might interact with molecular targets implicated in diabetic nephropathy. These computational analyses, which model the binding of a small molecule to the three-dimensional structures of proteins, supported the idea that erucic acid can engage inflammatory and oxidative stress mediators directly, providing a structural rationale for the biochemical changes observed in the animals. While docking results are hypotheses rather than proof, they offer a roadmap for future mechanistic studies aimed at pinpointing the precise signaling pathways—such as NF-kappa B and related inflammatory cascades—through which the fatty acid exerts its effects.

The authors are careful to frame these results as preclinical. Findings in streptozotocin-induced rats do not automatically translate to human diabetic kidney disease, and questions about optimal dosing, long-term safety, and the cardiac considerations historically associated with erucic acid consumption will need to be addressed before any clinical application. Nevertheless, the convergence of improved glycemic control, corrected dyslipidemia, restored antioxidant capacity, suppressed inflammatory cytokines, reduced tubular injury markers, and preserved kidney architecture paints a coherent and encouraging picture. As the global burden of diabetes continues to climb, with hundreds of millions of people at risk of diabetic nephropathy, the identification of an accessible, naturally derived fatty acid with multi-pronged kidney protection offers a compelling new lead in the search for therapies that can keep diabetic kidneys working longer.

Subject of Research: Renoprotective effects of erucic acid in streptozotocin-induced diabetic nephropathy in rats

Article Title: Renoprotective effects of the erucic acid in experimental diabetic nephropathy: antioxidant, anti-inflammatory, and in silico insights

Article References: Eid, T. M., Al-Abbasi, F. A., Afzal, M., Bawadood, A. S., Albishi, H. M., Alzarea, S. I., Chaieb, K., Sayyed, N., & Kazmi, I. (2026). Renoprotective effects of the erucic acid in experimental diabetic nephropathy: antioxidant, anti-inflammatory, and in silico insights. 3 Biotech, 16(9), Article 404. https://doi.org/10.1007/s13205-026-05041-1

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05041-1

Keywords: erucic acid, diabetic nephropathy, oxidative stress, inflammation, kidney disease, antioxidants, streptozotocin, KIM-1, NGAL, omega-9 fatty acid, molecular docking, renal function

The platform, which the researchers call human vascular organoid sheets, or hVOS, is built from two cell types derived from human pluripotent stem cells: endothelial cells, which line the interior of blood vessels, and smooth muscle cells, which form the muscular wall that gives vessels strength and control over blood flow. Conventional vascular organoids, while valuable for modeling human vascular biology, offer limited control over the ratio of cell types and their spatial arrangement. The hVOS approach overcomes this by using extrusion-based 3D bioprinting to deposit the two cell populations at a defined ratio within a bioink based on gelatin methacryloyl, a photocrosslinkable gelatin derivative widely used in tissue engineering. The printing is carried out under chemically defined culture conditions, which improves reproducibility and reduces the variability that has plagued earlier organoid systems.

Once printed, the cells do something remarkable: they self-assemble. Within the soft GelMA matrix, the endothelial cells and smooth muscle cells migrate, sort themselves, and organize into stable, interconnected vascular structures that progressively mature over time in culture. Functional assays and immunofluorescence imaging confirmed that the networks developed the hallmarks of genuine vasculature, including proper endothelial junctions and vessel-like architecture. The researchers then turned to single-cell RNA sequencing to interrogate the cellular composition at single-cell resolution. This revealed a diverse landscape of vascular and stromal populations and, importantly, identified transcriptional programs associated with vascular maturation, mechanotransduction, and hypoxic adaptation. In other words, the cells inside the printed sheets were not merely surviving; they were sensing their mechanical environment, responding to low oxygen, and actively remodeling toward a more mature vascular state.

The critical question, of course, is whether such engineered tissue can actually help a living organism. To find out, the team transplanted the hVOS into a murine model of hindlimb ischemia, a standard experimental setup in which blood flow to a mouse’s hindlimb is surgically restricted, mimicking the human condition of severe peripheral arterial disease. Using laser speckle perfusion imaging, a noninvasive optical technique that maps blood flow across tissue in real time, the researchers showed that animals receiving the bioprinted vascular sheets recovered significantly better blood perfusion than controls. The treatment also increased limb salvage, meaning fewer limbs deteriorated to the point of necrosis and loss, and histological analysis confirmed enhanced repair of the ischemic tissue.

Perhaps the most striking evidence came from intravital two-photon imaging, a technique that allows researchers to watch living tissue at cellular depth in a living animal. The team labeled the hVOS-derived cells with green fluorescent protein, and at both 14 and 28 days after transplantation they detected circulating dextran, a fluorescent tracer injected into the mouse’s bloodstream, flowing within the GFP-labeled vascular structures derived from the graft. This is the crucial demonstration: the human-derived vessels printed in the laboratory had become functionally connected to the host circulatory system, carrying the animal’s own blood. An engineered vascular graft that remains isolated from the host circulation is of limited use; one that is perfused by the host is a genuine piece of working plumbing.

But the study did not stop at showing that the graft worked. It asked what happened to the human cells inside the graft after transplantation, a question that has remained poorly understood in the field. By recovering graft-derived human cells from the mice and performing single-cell RNA sequencing on them, the researchers uncovered a process of substantial adaptive remodeling. The transplanted endothelial cells shifted toward venous-biased and inflammatory states, accompanied by activation of NF-κB signaling and stress-associated transcriptional programs. NF-κB is a central regulator of inflammatory responses, and its activation suggests that the graft endothelium was responding to the inflammatory cues of the wounded, ischemic environment. Rather than being a sign of failure, this remodeling appears to reflect the graft’s active participation in the repair process, with endothelial cells adjusting their identity and function to the demands of the host tissue.

The smooth muscle cells and fibroblasts within the graft underwent coordinated changes as well, showing transcriptional signatures associated with wound healing and extracellular matrix remodeling. The extracellular matrix, the fibrous scaffold that cells deposit around themselves, is central to tissue repair, providing both structural support and biochemical signals. The finding that graft-derived stromal cells were actively engaged in matrix remodeling suggests that the transplanted sheets did more than sprout vessels; they participated in the broader regenerative response of the injured tissue. Together, these single-cell results paint a picture of an engineered graft that is not a static implant but a dynamic, responsive tissue that negotiates with its new environment.

The implications for regenerative medicine are considerable. Because the hVOS are produced by bioprinting, the platform is design-flexible: the ratio of endothelial cells to smooth muscle cells, the geometry of the printed sheet, and the composition of the bioink can all be tuned. This reproducibility and controllability address two of the biggest obstacles that have held back vascular organoid technology from clinical translation, namely batch-to-batch variability and the inability to specify tissue architecture. A prevascularized construct that can be printed to order and implanted into ischemic tissue could, in principle, serve patients with peripheral arterial disease, diabetic wounds, myocardial infarction, or any condition in which inadequate blood supply limits healing.

At the same time, the study’s single-cell findings carry a cautionary and intellectually fascinating message for the field. The in vivo microenvironment reshaped the function of the graft’s endothelial cells, pushing them toward inflammatory and venous-like states. This means that the therapeutic properties of an engineered tissue cannot be fully predicted from its properties in the culture dish. The body actively reprograms transplanted cells, and understanding that reprogramming is essential both for optimizing graft design and for safety. If endothelial cells in a graft adopt strongly inflammatory states, for example, researchers will need to determine whether that inflammation is a productive part of vascular remodeling or a risk factor for graft dysfunction. The hVOS platform, by making graft-derived human cells recoverable and analyzable at single-cell resolution, provides exactly the tool needed to answer such questions systematically.

The work, published open access in BMC Medicine with contributions from Tsinghua University, Shanxi Medical University, and collaborating institutions, represents a convergence of stem cell biology, biofabrication, and computational genomics. Human pluripotent stem cells supply an unlimited and genetically defined source of vascular cells; extrusion bioprinting supplies the architectural control; and single-cell transcriptomics supplies a molecular accounting of what the engineered tissue does before and after it meets the body. As the field of vascular regenerative medicine moves toward clinical applications, studies like this one suggest that the future will belong not to simple cell injections but to engineered, multicellular, prevascularized tissues that are designed to integrate, adapt, and heal. The bioprinted vascular sheets described here are still at the preclinical stage, tested in mice, and substantial work remains before any human application. But the demonstration that printed human vessels can hook up to a living circulation and remodel themselves to serve the host is a milestone that makes the prospect of growing replacement vasculature feel considerably less like science fiction.

Subject of Research: 3D bioprinted human vascular organoid sheets for ischemic tissue repair and vascular regeneration

Article Title: 3D bioprinted human vascular organoid sheets promote functional ischemic repair and exhibit adaptive in vivo remodeling

Article References: Fu, X., Yan, L., Chen, Z., Dou, B., Zhou, D., Zhou, X., Qu, K., Gao, C., Wang, P., Zhang, F., Zou, Z., Wang, T., Li, G., Ouyang, L., & Na, J. (2026). 3D bioprinted human vascular organoid sheets promote functional ischemic repair and exhibit adaptive in vivo remodeling. BMC Medicine, 24(1), Article 524. https://doi.org/10.1186/s12916-026-05256-2

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05256-2

Keywords: 3D bioprinting, vascular organoids, human pluripotent stem cells, endothelial cells, smooth muscle cells, hindlimb ischemia, regenerative medicine, tissue engineering, single-cell RNA sequencing, angiogenesis, GelMA bioink, in vivo remodeling

Type 2 diabetes mellitus is one of the most pressing health challenges of the modern era, affecting hundreds of millions of people worldwide and projected to increase in prevalence through 2050. At the heart of the disease lies insulin resistance, a state in which the body’s tissues respond poorly to the hormone insulin, causing blood glucose to climb. Scientists have increasingly recognized that insulin resistance is not simply a problem of too much sugar; it is driven by a web of interlocking disturbances, including chronic low-grade inflammation, oxidative stress caused by reactive molecules, and dysfunction of mitochondria, the tiny organelles that generate chemical energy within cells. When mitochondria falter, they leak damaging signals that further inflame tissues and worsen metabolic control, creating a vicious cycle that standard therapies often address only indirectly.

Banxia Xiexin decoction, known historically as a remedy for gastrointestinal disorders, has in recent years attracted attention for its clinical benefits in patients with type 2 diabetes. Earlier work by some of the same researchers had shown that the formula could protect insulin-producing pancreatic beta cells from apoptosis, or programmed cell death, by activating the PI3K/AKT/FOXO1 signaling pathway. Yet the full inventory of its active compounds and the precise molecular routes by which they influence metabolism remained obscure. The new study was designed to close that gap using an ambitious multi-pronged strategy that blends big-data biology with classical pharmacology and animal experimentation.

The first pillar of the approach was network pharmacology, a discipline that treats a drug and a disease as two overlapping networks of molecular interactions. The researchers mined databases of herbal medicine constituents, filtering compounds by oral bioavailability and drug-likeness, and then mapped the targets of those compounds against genes known to be involved in type 2 diabetes. The analysis revealed 217 targets shared between the formula and the disease. Among the most prominent hub proteins were the inflammatory messengers interleukin-1 beta and tumor necrosis factor alpha, the insulin-signaling kinase AKT1, the nuclear receptor PPARG, and the longevity-associated deacetylase SIRT1. Pathway enrichment analysis highlighted the AMPK signaling pathway, a master regulator of cellular energy balance, as a key route through which the formula might exert its effects.

Network pharmacology alone, however, can only suggest associations. To strengthen the causal case, the team turned to summary-data-based Mendelian randomization, a statistical technique that uses naturally occurring genetic variation as a kind of randomized trial conducted by nature. By examining whether genetically predicted differences in the expression of candidate target genes are associated with diabetes risk, the researchers could ask which of the network’s hub proteins actually drive the disease rather than merely accompany it. The analysis identified AKT1 and SIRT1 as being causally linked to type 2 diabetes risk, elevating these two proteins to the status of prime mechanistic suspects. Molecular docking simulations then tested whether the formula’s constituent molecules could physically bind these targets, and found that quercetin, kaempferol, and wogonin attached stably to the key proteins.

Identifying which compounds actually reach the bloodstream after the formula is swallowed was the next challenge. Using ultra-high-performance liquid chromatography coupled with Q-Orbitrap high-resolution mass spectrometry, the researchers analyzed serum from animals given the decoction. They detected 18 prototype compounds absorbed intact, along with 53 metabolites produced as the body chemically transformed the original constituents. This pharmacokinetic fingerprint confirmed that the compounds flagged by the computational screens, including the flavonoids quercetin and kaempferol and the flavone wogonin, are genuinely present in circulation, lending biological plausibility to the predicted drug-target interactions.

The decisive test came in living animals. The researchers induced diabetes in C57BL/6J mice using a combination of a high-fat diet and streptozotocin, a chemical that damages pancreatic beta cells and produces a metabolic picture closely resembling human type 2 diabetes. The diabetic mice were treated with Banxia Xiexin decoction for eight weeks, and the results were striking. Treated animals showed significantly lower fasting blood glucose and reduced HOMA-IR, a standard index of insulin resistance. Glucose tolerance tests and insulin tolerance tests both improved, with treated mice showing smaller areas under the response curves, indicating that their bodies regained sensitivity to insulin and handled dietary sugar more effectively.

The formula’s benefits extended beyond glucose control to the inflammatory and oxidative dimensions of the disease. Treated mice had reduced levels of tumor necrosis factor alpha, interleukin-1 beta, reactive oxygen species, and malondialdehyde, a lipid-damage marker, while the activity of superoxide dismutase, a natural antioxidant enzyme, was restored. Under the microscope, adipose tissue from treated animals retained healthier morphology than that of untreated diabetic controls, suggesting protection of fat tissue function, which is itself a critical determinant of whole-body insulin sensitivity. Together, these observations indicated that the decoction was not merely masking high blood sugar but was intervening in the underlying pathological processes that sustain the disease.

At the molecular level, the study’s mechanistic story centered on the AMPK/SIRT1 axis and mitophagy. AMP-activated protein kinase, or AMPK, acts as a cellular fuel gauge, switching on energy-conserving and quality-control programs when nutrients are scarce, while SIRT1, a sirtuin enzyme dependent on the molecule NAD+, coordinates metabolic adaptation and inflammation control. In the treated mice, the researchers observed activation of this pathway, accompanied by enhanced mitophagy, the selective autophagic removal of damaged mitochondria. Markers of this process shifted in a coherent direction: levels of PINK1 and Parkin, proteins that tag defective mitochondria for destruction, increased, as did the ratio of LC3-II to LC3-I, a hallmark of autophagosome formation, while p62, a cargo receptor that accumulates when autophagy is blocked, decreased. The formula also upregulated PPARG and phosphorylated AKT1, reinforcing insulin signaling in metabolic tissues.

The significance of this work lies not only in validating an ancient remedy but in demonstrating a template for how traditional medicine can be interrogated with modern tools. By triangulating between computational target prediction, genetic causal inference, serum pharmacokinetics, and controlled animal experiments, the researchers built a chain of evidence in which each link supports the next, reducing the risk that observed benefits are artifacts of any single method. The authors caution that their findings constitute mechanistic evidence supporting further translational investigation rather than proof of clinical efficacy, and the mouse model, while informative, cannot capture every facet of human diabetes. Nevertheless, the identification of the AMPK/SIRT1-mitophagy axis as a target of Banxia Xiexin decoction offers a concrete molecular hypothesis that can now be tested in human studies, potentially opening a path toward evidence-based integration of this centuries-old formula into the therapeutic arsenal against type 2 diabetes.

Subject of Research: Therapeutic mechanism of the traditional Chinese medicine formula Banxia Xiexin decoction in type 2 diabetes mellitus via the AMPK/SIRT1-mitophagy pathway

Article Title: Combining network pharmacology and experimental validation to explore the therapeutic mechanism of Banxia Xiexin decoction in type 2 diabetes mellitus

Article References: Du, L., Chen, Y., Zhang, X., Han, Y., Qin, G., Tang, Y., Han, S., Yang, Y., Zhao, Q., & Song, S. (2026). Combining network pharmacology and experimental validation to explore the therapeutic mechanism of Banxia Xiexin decoction in type 2 diabetes mellitus. 3 Biotech, 16(10), Article 406. https://doi.org/10.1007/s13205-026-05001-9

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05001-9

Keywords: type 2 diabetes mellitus, Banxia Xiexin decoction, network pharmacology, AMPK/SIRT1 pathway, mitophagy, insulin resistance, traditional Chinese medicine, quercetin, kaempferol, wogonin, Mendelian randomization, oxidative stress

At the heart of the discipline sit synthetic genetic circuits, which the authors describe as the basic building blocks of the entire enterprise. These circuits control the production, turnover or depletion of specific DNA, RNA or protein molecules, giving researchers programmable control over gene expression and cellular behavior. The repertoire includes logic gates that mirror digital electronics, with BUFFER, NOT, AND, OR, XOR, NAND, NOR and XNOR configurations each activating or repressing output genes under distinct input conditions. Oscillators generate rhythmic fluctuations in protein concentrations, echoing natural circadian clocks and cell cycle regulators, while toggle switches act as biological memory, holding gene expression stably on or off much like flip-flop circuits in electronics. The landmark repressilator built by Elowitz and Leibler in Escherichia coli, a ring of three repressor proteins that suppress one another in sequence, produced green fluorescent protein oscillations with a period of roughly 150 minutes, about three times longer than the cell division cycle, demonstrating that entirely artificial networks could function robustly inside living bacteria.

The clinical implications of these circuits are already substantial. Genetic switches integrated into human cells can detect internal disease signals and respond with closed-loop logic, or react to external molecular cues in an open-loop configuration. When such circuits are built into next-generation chimeric antigen receptor T cells, they allow precise control over the timing and intensity of immune responses, improving both safety and effectiveness. A study by Daniels and colleagues designed more than 1,200 receptors combining twelve different signaling motifs and, using machine learning, identified synthetic motifs absent from natural receptors that created new T cell phenotypes with enhanced antitumor efficacy. In parallel, Li and colleagues developed synthetic zinc finger transcription factors, called synZiFTRs, that target an artificial 18-base-pair promoter not found in the human genome. Their activity could be controlled with three FDA-approved drugs: the antiviral grazoprevir induced anti-HER2 CAR expression in T cells, while tamoxifen triggered production of super high-affinity IL-2, producing drug-controllable antitumor effects in mouse models of NALM6 leukemia.

Synthetic chromosomes represent an even bolder frontier. Jason Chin’s team synthesized the entire E. coli genome, roughly four times larger than any previously synthesized genome, and compressed its genetic code from 64 to 61 codons by recoding 18,214 codon instances, using the REXER method to progressively replace the native genome with the synthetic version across eight parallel strains that were then combined by conjugation. In eukaryotes, the Sc2.0 Synthetic Yeast Genome Project, led by Jef Boeke of Johns Hopkins University, aims to build a designer genome for Saccharomyces cerevisiae, a organism with roughly 6,000 genes. Its signature SCRaMbLE system embeds more than 5,000 loxP recombination sites that can be rapidly activated to shuffle genetic content, generating millions of cell variants from which strains with improved industrial traits can be selected. After ten years of intensive work, an international collaboration spanning the UK, USA, China, Singapore, France and Australia completed synthetic chromosome XI, a 660,000-base-pair sequence that replaced a natural yeast chromosome while preserving normal cellular fitness through rigorous error correction.

Metabolic engineering, a discipline that emerged in the 1990s, is delivering some of the field’s most tangible products. Jay Keasling’s team engineered Saccharomyces cerevisiae to produce artemisinic acid, the precursor to the antimalarial drug artemisinin, by inserting and optimizing genes from multiple organisms including the malaria parasite Plasmodium falciparum, creating a sustainable fermentation route that sidesteps the variability of plant extraction. Lee and colleagues achieved something once thought impossible: engineered E. coli producing 1,4-butanediol, an industrial chemical made in more than 2.5 million tons annually that no living organism produces naturally, at a yield of 18 grams per liter from renewable sugars including glucose, xylose and sucrose. On the energy front, Nielsen and colleagues developed three microbial platforms, based on Saccharomyces cerevisiae, Zymomonas mobilis and E. coli, capable of fermenting lignocellulose sugars into bioethanol, though the authors note that competitive production will require optimization across every stage of the process. Dynamic metabolic control has also matured: by rewiring the transcriptional regulator FapR to balance malonyl-CoA supply and consumption in E. coli, researchers achieved a 15.7-fold improvement in fatty acid production.

The tools that make all of this possible have themselves undergone a quiet revolution. Standardized cloning remains foundational, with plasmids carrying replication origins, selection markers and promoters serving as the workhorses of gene transfer, and modular systems such as SureVector accelerating vector assembly. BioBrick standard parts, stored in the Standard Biological Parts Registry and central to the international iGEM competition, embody the field’s commitment to abstraction and interchangeability. Gibson assembly allows multiple DNA fragments with homologous overlapping ends to be joined seamlessly in an hour or less without restriction enzymes, while Golden Gate assembly and its extensions, including MoClo and Golden Braid, use type IIS enzymes to combine many fragments in a single tube. De novo DNA synthesis now delivers designed sequences within days or weeks, though cost and accuracy remain limiting factors. Perhaps most conceptually important is the chassis: researchers at the J. Craig Venter Institute, starting from Mycoplasma genitalium, progressively defined a minimal cell, and by 2016 produced a organism with just 473 genes across 531 kilobase pairs, a simplified biological platform that minimizes interference with engineered circuits.

Beyond cancer, the review documents synthetic biology’s reach into diagnostics, tissue engineering and drug delivery. Engineered E. coli that produce LacZ upon contacting tumor cells can detect tumors smaller than one centimeter through a simple urine luminescence test, while Salmonella enterica colonizing tumor tissue can convert a prodrug into 5-fluorouracil that eradicates cancer cells. In tissue engineering, synthetic circuits built on Tet-on and Tet-off systems allow temporally controlled expression of genes such as Runx2 and Sox9, guiding bone and cartilage formation in implanted scaffolds, and biomaterial-encased gene switches have sustained reporter expression for more than 300 days in some systems. Bottom-up synthetic cells are emerging as drug carriers: Chen and colleagues built synthetic beta cells from multi-compartment vesicles containing glucose oxidase, catalase and insulin-loaded liposomes that released insulin in response to glucose and normalized blood sugar in type 1 diabetic mice, while other synthetic cells producing Pseudomonas exotoxin A killed cancer cells more effectively than purified toxin alone.

Biosensors and anti-infective therapies round out the medical portfolio. The ROSALIND platform developed by Collins and colleagues uses cell-free, freeze-dried reactions with allosteric transcription factors to detect 16 different water contaminants, producing visible RNA-based signals that can be shipped at ambient temperature and deployed in field tests on municipal water. Against antibiotic resistance, engineered phages have shown striking results: a T7 phage producing the biofilm-degrading enzyme dispersin B eliminated 99.997 percent of bacteria within a biofilm, and a lytic M13 phage suppressing bacterial DNA damage responses significantly enhanced the killing of resistant cells by existing antibiotics. Phage display technology, pioneered by George Smith and applied to antibodies by Gregory Winter, underlies drugs such as adalimumab for rheumatoid arthritis, and AI tools like AlphaFold are now accelerating therapeutic antibody design by modeling binding sites with unprecedented speed and accuracy.

Agriculture and industry complete the picture, alongside sobering warnings. Pivot Bio’s engineered nitrogen-fixing bacteria increased corn yields by 5.8 bushels per acre while cutting chemical fertilizer use by 25 pounds per acre, without the greenhouse gas emissions and runoff of conventional fertilizers. CRISPR/Cas9 editing has boosted GABA content in tomatoes seven- to fifteen-fold, raised lycopene levels 5.1-fold through multiplex editing, and enabled de novo domestication of allotetraploid wild rice by Jiayang Li’s team. Even de-extinction has entered the agenda, with George Church’s project aiming to modify around 45 genes in the Asian elephant genome to create a cold-tolerant, mammoth-like hybrid. Yet the authors close with a caution: the same tools that promise sustainable fuels and personalized medicines could, through accident or intent, produce harmful biological agents, and they argue that strong biosafety and biosecurity policies at national and global levels are a critical precondition for safely delivering synthetic biology’s benefits to society. By 2030, they predict, most people will use a product built by this technology, whether they know it or not.

Subject of Research: Applications of synthetic biology in medicine, agriculture and industry

Article Title: Synthetic biology and application areas

Article References: Karataş, P., & Ayaz, F. (2025). Synthetic biology and application areas. Discover Biotechnology, 2(1), Article 3. https://doi.org/10.1007/s44340-025-00010-5

Image Credits: AI Generated

DOI: 10.1007/s44340-025-00010-5

Keywords: synthetic biology, genetic circuits, CAR-T cell therapy, synthetic chromosomes, metabolic engineering, CRISPR, biosensors, drug delivery, biofuels, Sc2.0 yeast genome, repressilator, biosecurity

Anaerobic digestion is the biological workhorse behind most biogas production. In oxygen-free reactors, communities of hydrolytic bacteria break down complex organic molecules into sugars, amino acids and fatty acids. Acidogenic microbes then ferment these intermediates into volatile fatty acids, hydrogen and carbon dioxide, which acetogens convert to acetate. Finally, methanogenic archaea, a group of microorganisms evolutionarily distinct from bacteria, transform acetate and hydrogen into methane, the energy-dense core of biogas. The process works beautifully at mesophilic temperatures of roughly 35 degrees Celsius, where microbial enzymes operate at peak efficiency. But heating a digester consumes energy, and in cold regions of the world, from high-altitude Himalayan villages to northern temperate cities, maintaining those temperatures can erase much of the energy benefit that biogas is supposed to deliver.

Blackwater alone presents a paradox for digester operators. It is rich in organic matter, which should make it excellent fuel for methane production, yet its dilute nature and its chemical composition undermine the very microbial consortia needed to unlock that energy. The review highlights two principal inhibitors. The first is ammonia, released from the urea and proteins abundant in human excreta. At elevated concentrations, free ammonia diffuses into microbial cells and disrupts pH gradients, hitting acetoclastic methanogens, the archaea that split acetate into methane and carbon dioxide, particularly hard. The second is sulfate, which fuels sulfate-reducing bacteria that compete with methanogens for hydrogen and acetate. When sulfate reducers win that competition, electrons that could have become methane end up as hydrogen sulfide instead, cutting methane yields and producing a corrosive, toxic gas that must be scrubbed from the biogas stream.

Food waste, by contrast, is an energy powerhouse but a chemically unbalanced one. Kitchen scraps are loaded with carbohydrates, fats and proteins that can drive high methane yields, yet they typically carry a carbon-to-nitrogen ratio that is either too high or too variable, and their rapid acidification can crash a digester’s pH within hours. The central insight of the review is that these two feedstocks are complementary in almost every respect. Food waste brings a concentrated, readily biodegradable carbon supply; blackwater brings water, buffering capacity, alkalinity and a suite of trace nutrients. Blended in the right proportions, the mixture dilutes the ammonia and sulfate that plague blackwater mono-digestion while stabilizing the volatile fatty acid surges that plague food waste mono-digestion. The result is a synergistic system in which the weaknesses of each substrate are offset by the strengths of the other.

Getting the mixing ratio right, however, is a delicate balancing act, and the review devotes considerable attention to it. Too much food waste and the digester acidifies, accumulating volatile fatty acids faster than methanogens can consume them. Too much blackwater and ammonia inhibition reasserts itself, especially at low temperatures where microbial metabolism slows and inhibitory compounds linger longer. Studies cited in the review, including work on vacuum-toilet blackwater co-digested with kitchen waste, suggest that carefully tuned ratios can shift the dominant methanogenic pathway from acetoclastic to hydrogenotrophic methanogenesis, a route in which archaea combine carbon dioxide with hydrogen to build methane. Hydrogenotrophic methanogens tend to be more ammonia-tolerant, and syntrophic acetate-oxidizing bacteria can partner with them to oxidize acetate into hydrogen and carbon dioxide, effectively routing around the most ammonia-sensitive step in the food web.

Low-temperature operation, typically below 20 degrees Celsius, adds another layer of complexity. Psychrophilic and psychrotolerant microbes have evolved molecular adaptations, including flexible enzymes and cold-stabilized membranes, that allow them to function where mesophilic organisms grind to a halt. The review describes how cold-adapted biomass can be developed through gradual acclimatization, in which digester communities are slowly conditioned to falling temperatures, allowing populations of cold-active methanogens and hydrolytic bacteria to expand. Studies of long-term low-temperature anaerobic digestion of sewage and dairy wastewater show that microbial communities can restructure themselves, with genera such as Methanosarcina, Methanoculleus and various hydrogenotrophic archaea taking on larger roles. Biomass retention becomes critical in this regime: because cold microbes grow slowly, reactors must hold onto their microbial workforce rather than washing it out with the effluent.

Reactor engineering offers several solutions to the retention problem, and the review evaluates them in detail. Upflow anaerobic sludge blanket reactors rely on dense granules of microbes that settle and remain in the vessel while treated water exits the top. Anaerobic membrane bioreactors use physical filtration to retain even the smallest cells, and studies have demonstrated their operation at temperatures as low as 3 degrees Celsius. Anaerobic hybrid systems combine sludge blankets with packed-bed or filter media that provide surfaces for biofilm growth. Additives can also help: granular activated carbon and biochar provide conductive surfaces that promote direct interspecies electron transfer, allowing microbes to exchange electrons without relying solely on hydrogen or formate as intermediates. Trace element supplementation with iron, selenium, cobalt and molybdenum supports the metalloenzymes at the heart of methanogenesis, and micronutrient dosing has repeatedly been shown to stabilize co-digestion under stress.

Beyond energy, the co-digestion approach delivers sanitation and resource-recovery benefits that align with circular economy thinking. Anaerobic digestion substantially reduces pathogen loads in blackwater, and the digestate retains nitrogen and phosphorus that can be recovered as fertilizer. The review points to struvite precipitation as a proven route for extracting phosphorus from source-diverted blackwater, turning a disposal problem into an agricultural input. Decentralized systems are a particularly compelling application: a neighborhood-scale digester fed by vacuum-collected blackwater and local food waste could provide cooking gas and fertilizer while reducing the burden on centralized sewage infrastructure. For cold-climate regions and remote communities where conventional wastewater treatment is expensive or absent, such systems could close the loop between sanitation, food and energy.

The review is candid about the gaps that remain before blackwater-food waste co-digestion can be deployed at scale in cold climates. Most published studies operate at laboratory or pilot scale under mesophilic or thermophilic conditions, and direct evidence for long-term, stable low-temperature co-digestion of these specific feedstocks is still thin. Questions about optimal organic loading rates, the kinetics of hydrolysis at low temperatures, the long-term dynamics of antibiotic resistance genes in digestate, and the economics of decentralized deployment all demand further research. The authors also flag the need for life-cycle assessments to confirm that the energy recovered genuinely exceeds the energy invested, particularly in systems that require feedstock transport or modest heating. Nevertheless, the synthesis makes a persuasive case that the synergy between blackwater and food waste is real, mechanistically grounded and worth pursuing.

What emerges from this body of work is a vision of sanitation infrastructure reimagined as an energy asset rather than a liability. The microbes that transform human waste and kitchen scraps into methane are among the oldest metabolic machines on Earth, and with the right reactor design, mixing ratios and cold-adapted communities, they can be coaxed to work even where winter temperatures would once have ruled anaerobic digestion out of the question. As the world searches for ways to cut methane emissions from landfills and sewage systems while expanding access to clean cooking fuel, the humble combination of toilet wastewater and food scraps may prove to be one of the most practical synergies in the bioenergy toolkit, provided that researchers can carry the promise from the laboratory bench into the cold realities of the field.

Subject of Research: Low-temperature anaerobic co-digestion of blackwater and food waste for biomethane production

Article Title: Blackwater and food waste: a sustainable synergy for low-temperature biomethane

Article References: Justina, D. E.-A., Saikia, S., Baruah, D. C., & Chatterjee, S. (2026). Blackwater and food waste: a sustainable synergy for low-temperature biomethane. 3 Biotech, 16(10), Article 422. https://doi.org/10.1007/s13205-026-04999-2

Image Credits: AI Generated

DOI: 10.1007/s13205-026-04999-2

Keywords: blackwater, food waste, anaerobic digestion, co-digestion, biomethane, low temperature, psychrophilic, methanogens, ammonia inhibition, biogas, circular economy, sanitation